What we're reading, April 20, 2016: Tufts Health Plan will pay for hepatitis C drugs for all patients with the disease; drug advertisements don't sway consumers; and Express Scripts countersues Anthem.
Tufts Health Plan, based in Massachusetts, will now pay for expensive hepatitis C drugs regardless of the patient’s disease stage. The change in policy comes amidst public outrage over insurers limiting the drugs to people with severe liver damage despite medical guidelines recommending treating nearly every infected person, according to The Boston Globe. Blue Cross Blue Shield of Massachusetts also pays for the hepatitis C drugs regardless of how much liver damage a patient has, but most insurers in Massachusetts require evidence of advanced liver disease.
Few consumers say drug advertisements prompt them to speak with a doctor about the medicine being promoted. With only 7% of people surveyed saying they spoke with a doctor about a drug after seeing the advertisement for it, people may not be swayed by direct-to-consumer advertising, reported STAT. However, spending on drug ads on TV was up 31% from 2014 to 2015 and the pharmaceutical industry spent $5.4 billion total on advertising last year.
Express Scripts is countersuing Anthem, which first sued the pharmacy benefit manager in March for allegedly violating its contract by refusing to renegotiate pricing terms. According to The Wall Street Journal, Express Scripts denied Anthem’s allegations and filed a lawsuit demanding unspecific damages from Anthem and a judgment that Anthem cannot end the contract. Express Scripts is now alleging that Anthem has refused to negotiate in good faith.
Long COVID Disparities Revealed in New Study From England
March 18th 2025A new analysis out of England shows a considerable level of uncertainty among adults who think they could have long COVID, as well that levels of the chronic condition are disproportionately higher among certain socially disadvantaged groups.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen